Solu Therapeutics, a biotechnology company specializing in developing therapeutics to target disease-causing cells using its CyTaCTM (Cytotoxicity Targeting Chimera) platform, has appointed Michael I. Boretti, Ph.D., as Chief Business Officer (CBO).
With over 15 years of leadership experience in biotechnology, Dr. Boretti has a proven track record in company development and deal-making across various therapeutic areas. In his role as CBO, he will spearhead Solu’s business development strategy, strategic financing, and alliance management efforts.
“Solu’s innovative CyTaC platform offers a novel approach to targeting previously inaccessible disease-causing cells, offering potential benefits across a wide range of medical conditions,” stated Dr. Boretti. “I am thrilled to join the dedicated Solu team to drive the development of groundbreaking medicines that can improve patients’ lives.”
